W. McLean Provan

1.1k citations

15 papers · 884 · h-index 13

Impact in

Clinical Biochemistry top 1%
- Metabolism and Genetic Disorders
Biochemistry top 5%
- Amino Acid Enzymes and Metabolism

Papers in

Clinical Biochemistry 6
- Metabolism and Genetic Disorders 6
Biochemistry 6
- Amino Acid Enzymes and Metabolism 4
- Biochemical Acid Research Studies 2

Co-authors: Martin K. Ellis (7 shared papers)Edward A. Lock (7 shared papers)Lewis L. Smith (7 shared papers)Linda Mutter (3 shared papers)Michael P. Prisbylla (3 shared papers)Mervyn Robinson (4 shared papers)T.R. Auton (2 shared papers)David L. Lee (2 shared papers)
Journals: Toxicology and Applied Pharmacology (6 papers)Toxicology (1 paper)Weed Science (1 paper)British Journal of Clinical Pharmacology (1 paper)Human & Experimental Toxicology (1 paper)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

W. McLean Provan

15 papers receiving 838 citations

Peers

Replace Martin K. Ellis with:

Martin K. Ellis United Kingdom

J. E. Bakke United States

Adelbert E. Wade United States

Sybil P. James United Kingdom

W. Koransky Germany

L. L. Danielson Sweden

Preston H. Grantham United States

Erik Arrhenius Sweden

T. Kamataki Japan

N. Dı́az-Alejo Spain

W. McLean Provan relative to Martin K. Ellis United Kingdom Martin K. Ellis's profile →

Citations per field

00.5×1.5×1.8×

Martin K. Ellis · 1×

×1.3 252/189

CB

×1.1 162/145

BIOCH

×1.8 108/61

PHARM

×1.5 140/92

CR

×0.9 116/124

POLLU

Citations per year

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

'26

Countries citing papers authored by W. McLean Provan

Since Specialization

Citations

This map shows the geographic impact of W. McLean Provan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. McLean Provan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. McLean Provan more than expected).

Fields of papers citing papers by W. McLean Provan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. McLean Provan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. McLean Provan. The network helps show where W. McLean Provan may publish in the future.

Co-authors

The 25 scholars most cited alongside W. McLean Provan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with W. McLean Provan Line = papers co-authored together W. McLean Provan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work
1	The discovery and structural requirements of inhibitors of p-hydroxyphenylpyruvate dioxygenase Weed Science ·David L. Lee, Michael P. Prisbylla, Thomas H. Cromartie, Derek P. Dagarin, Stott Howard, W. McLean Provan, Martin K. Ellis, Torquil Fraser, Linda Mutter	1997	170
2	Species differences in response to trichloroethylene Toxicology and Applied Pharmacology ·M.S. Prout, W. McLean Provan, T. Green	1985	127
3	Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione Toxicology and Applied Pharmacology ·Martin K. Ellis, Alison C. Whitfield, Lesley A. Gowans, T.R. Auton, W. McLean Provan, Edward A. Lock, Lewis L. Smith	1995	95
4	From toxicological problem to therapeutic use: The discovery of the mode of action of 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC), its toxicology and development as a drug Journal of Inherited Metabolic Disease ·Edward A. Lock, Martin K. Ellis, Peter Gaskin, Mervyn Robinson, T.R. Auton, W. McLean Provan, Lewis L. Smith, Michael P. Prisbylla, Linda Mutter, D. L. Lee	1998	89
5	Effect of intestinal microflora on the urinary metabolic profile of rats: a 1 H-nuclear magnetic resonance spectroscopy study Xenobiotica ·Rebecca E. Williams, H. W. Eyton-Jones, Mark J. Farnworth, Rachael V. Gallagher, W. McLean Provan	2002	82
6	Pharmacokinetics and pharmacodynamics of NTBC (2‐(2‐nitro‐4‐fluoromethylbenzoyl)‐1,3‐cyclohexanedione) and mesotrione, inhibitors of 4‐hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers British Journal of Clinical Pharmacology ·Michael G. Hall, Martin F. Wilks, W. McLean Provan, Staffan Eksborg, Bo Lumholtz	2001	77
7	Predicting Cancer Risk from Vinyl Chloride Exposure with a Physiologically Based Pharmacokinetic Model Toxicology and Applied Pharmacology ·Richard H. Reitz, Michael L. Gargas, Melvin E. Andersen, W. McLean Provan, Trevor L. Green	1996	58
8	Tissue Distribution of 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione (NTBC): Effect on Enzymes Involved in Tyrosine Catabolism and Relevance to Ocular Toxicity in the Rat Toxicology and Applied Pharmacology ·Edward A. Lock, Peter Gaskin, Martin K. Ellis, W. McLean Provan, Mervyn Robinson, Lewis L. Smith, Michael P. Prisbylla, Linda Mutter	1996	41
9	Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse Toxicology ·Edward A. Lock, Peter Gaskin, Martin K. Ellis, W. McLean Provan, Mervyn Robinson, Lewis L. Smith	2000	32
10	Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury Toxicology and Applied Pharmacology ·Edward A. Lock, Peter Gaskin, M. Ellis, W. McLean Provan, Lewis L. Smith	2006	28
11	Characterization of the Interaction of 2-[2-Nitro-4-(trifluoromethyl)benzoyl]-4,4,6,6-tetramethylcyclohexane-1,3,5-trione with Rat Hepatic 4-Hydroxyphenylpyruvate Dioxygenase Chemical Research in Toxicology ·Martin K. Ellis, Alison C. Whitfield, Lesley A. Gowans, Tim Auton, W. McLean Provan, Edward A. Lock, David L. Lee, Lewis L. Smith	1996	28
12	The Integrated Use of Alternative Approaches for Predicting Toxic Hazard Alternatives to Laboratory Animals ·Martin D. Barratt, José V. Castell, M. Chamberlain, Robert D. Combes, John C. Dearden, Julia H. Fentem, Ingrid Gerner, Alessandro Giuliani, Tim J.B. Gray, David J. Livingstone, W. McLean Provan, Fons A.J.J.L. Rutten, Henk J. M. Verhaar, Peter Zbinden	1995	26
13	The Effect of a Low-Protein Diet and Dietary Supplementation of Threonine on Tyrosine and 2-(2-Nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-Induced Corneal Lesions, the Extent of Tyrosinemia, and the Activity of Enzymes Involved in Tyrosine Catabolism in the Rat Toxicology and Applied Pharmacology ·Edward A. Lock, Peter Gaskin, Martin K. Ellis, Mervyn Robinson, W. McLean Provan, Lewis L. Smith	1998	19
14	The incorporation of radiolabelled sulphur from captan into protein and its impact on a DNA binding study Chemico-Biological Interactions ·W. McLean Provan, H. Eyton-Jones, Graham Lappin, David G. Pritchard, Richard B. Moore, T. Green	1995	10
15	Comparison of Two Methods for Determining the Toxicokinetics of Fluazifop-butyl after Intravenous Dosing in Rats Human & Experimental Toxicology ·John M. Rawlings, W. McLean Provan, Martin F. Wilks, Peter L. Batten	1994	2

About W. McLean Provan

W. McLean Provan is a scholar working on Clinical Biochemistry, Biochemistry, Molecular Biology, Neurology and Cancer Research, having authored 15 papers that have together received 884 indexed citations. Recurring topics across this work include Metabolism and Genetic Disorders (6 papers), Amino Acid Enzymes and Metabolism (4 papers), Alcoholism and Thiamine Deficiency (3 papers), Biochemical Acid Research Studies (2 papers), Carcinogens and Genotoxicity Assessment (2 papers), Folate and B Vitamins Research (1 paper), Glutathione Transferases and Polymorphisms (1 paper) and Peroxisome Proliferator-Activated Receptors (1 paper). The work is most often cited by research in Clinical Biochemistry (252 citations), Biochemistry (162 citations), Pharmacology (108 citations), Cancer Research (140 citations) and Pollution (116 citations). W. McLean Provan has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Martin K. Ellis, Edward A. Lock, Lewis L. Smith, Linda Mutter, Michael P. Prisbylla, Mervyn Robinson, T.R. Auton, David L. Lee, Thomas H. Cromartie and Torquil Fraser. Their work appears in journals such as Toxicology and Applied Pharmacology, Toxicology, Weed Science, British Journal of Clinical Pharmacology and Human & Experimental Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

W. McLean Provan

Impact in

Papers in i

In The Last Decade

W. McLean Provan

Peers

Countries citing papers authored by W. McLean Provan

Fields of papers citing papers by W. McLean Provan

All Works

About W. McLean Provan

Explore authors with similar magnitude of impact

Papers in